Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIM Artificial Tears is a preservative-free ophthalmic salt solution used as an ocular lubricant for the treatment of dry eye disease. It is formulated to mimic the electrolyte balance of natural tears, providing hydration and stabilizing the tear film to protect the ocular surface from irritation and desiccation. In a randomized, double-blind clinical trial sponsored by Chang Gung Memorial Hospital (NCT03186092), this salt solution served as the control intervention to evaluate the supplemental efficacy of 0.15% hyaluronic acid (Per-Young Eye Drops) in patients with dry eye. The product is typically administered multiple times daily to alleviate symptoms such as ocular dryness, redness, and foreign body sensation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AIM Artificial Tears.